17 completed. 17 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 1 | Completed 1 |
Follow Pleural Effusion, Malignant: new trials by email Literature Review of Pleural Effusion, Malignant trials Research Report on Pleural Effusion, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | RS Oncology LLC | 50 | 2022-03-31 | 2026-07-24 |
| Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. Nivolumab - Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | Kidney Cancer Research Bureau | 26 | 2020-08-10 | 2023-03-08 |
| Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer intrapleural docetaxel administration - Pleural Effusion, Malignant, Non-small Cell Carcinoma | Phase 2 | Completed | Asan Medical Center | 4 | 2016-07-26 | 2019-03-08 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer Bevacizumab - Non-small Cell Lung Cancer, Malignant Pleural Effusion | Phase 2 | Completed | Haihong Yang, MD, Pricipal investigator | 22 | 2014-01-01 | 2019-03-29 |
| Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Endostar, Cisplatin - Malignant Pleural Effusion, Malignant Ascites | Phase 2 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 336 | 2011-03-01 | 2014-08-01 |
| Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer carboplatin, cisplatin, paclitaxel - Fallopian Tube Cancer, Metastatic Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 275 | 2010-03-03 | 2023-08-28 |
| Tunneled Pleural Catheter in Partially Entrapped Lung VATS, Talc-Pleurodesis, tunneled pleural drainage, VATS, Talc-pleurodesis - Malignant Pleural Effusion | Phase 2 | Completed | Heidelberg University | 50 | 2008-07-01 | 2022-09-02 |
| AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer saracatinib - Extensive Stage Small Cell Lung Cancer, Lung Metastases | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2007-11-01 | 2017-12-07 |
| FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer carboplatin, docetaxel, gemcitabine hydrochloride - Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Completed | University of Washington | 55 | 2007-10-01 | 2017-02-10 |
| A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC Cetuximab, Bevacizumab, Paclitaxel - Non-Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 121 | 2006-12-01 | 2011-06-07 |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer imatinib mesylate, paclitaxel - Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer | Phase 2 | Completed | University of Washington | 34 | 2006-02-01 | 2017-04-25 |
| Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer Alimta - Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2005-09-01 | 2017-02-13 |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Carboplatin, Erlotinib, Erlotinib Hydrochloride - Lung Adenocarcinoma, Lung Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 188 | 2005-08-15 | 2019-08-07 |
| Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer docetaxel, cetuximab, bortezomib - Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 62 | 2005-07-01 | 2013-06-04 |
| The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer Vinorelbine, Docetaxel, Gemcitabine - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 53 | 2004-02-01 | 2017-03-23 |
| Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer docetaxel (Taxotere®), ZD1839 - Non-Small Cell Lung Cancer | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 44 | 2003-07-01 | 2017-03-03 |
Carcinoma, Non-Small-Cell Lung (8) · Adenocarcinoma of Lung (2) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Pericardial Effusion (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Brenner Tumor (1) · Lung Neoplasms (1) · Mesothelioma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1)
Neoplasms (17) · Neoplasms by Site (17) · Pleural Diseases (17) · Pleural Effusion (17) · Pleural Neoplasms (17) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (17) · Thoracic Neoplasms (17) · Lung Diseases (10) · Lung Neoplasms (10) · Bronchial Neoplasms (9) · Carcinoma, Bronchogenic (9) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Carcinoma (4)
Carboplatin (5) · Paclitaxel (5) · Docetaxel (4) · Taxes (3) · Bevacizumab (2) · Cetuximab (2) · Cisplatin (2) · Gemcitabine (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Bortezomib (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Fluorodeoxyglucose F18 (1) · Gefitinib (1) · Imatinib Mesylate (1)
National Cancer Institute (NCI) (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · University of Washington (2) · Asan Medical Center (1) · Canadian Cancer Trials Group (1) · Eli Lilly and Company (1) · Haihong Yang, MD, Pricipal investigator (1) · Heidelberg University (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Kidney Cancer Research Bureau (1) · M.D. Anderson Cancer Center (1) · RS Oncology LLC (1) · University of Chicago (1)
United States (11) · China (2) · United Kingdom (2) · Canada (1) · Germany (1) · Russia (1) · South Korea (1) · Spain (1)
Alberto Chiappori, MD (1) · Diane M. Provencher, MD, FRCS, FACOG (1) · Gerold Bepler, MD, PhD (1) · Haihong Yang, MD (1) · Hans Hoffmann, MD, PhD (1) · Helen J. Mackay, MD (1) · Ilya Tsimafeyeu, M.D. (1) · James Spicer, MD (1) · Julian Molina (1) · Keith Eaton (1) · Pasi A Janne (1) · Ralph Zinner, MD (1) · Renato Martins (1)
PMID 18300255, PMID 27007334, PMID 29186319, PMID 42448681
U10CA031946 (2), R21CA123866 (1), U10CA025224 (1), U10CA180821 (1)